About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Depression Clinical Trials in Houston | 189 Studies | Clareo Health

Clinical Trials DepressionHouston

Depression Clinical Trials in Houston

Find 189 clinical trials for depression near Houston, Texas. Connect with research centers in your area.

All Depression trials nationwide All trials in Houston

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 121-140 of 189 trials

COMPLETEDNA< 1 mile

Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions

NCT01107353

The objective of this study was to prove the bioequivalence of Imipramine Pamoate 75 mg Capsules under fasting conditions

Roxane Laboratories39 participantsStarted Aug 2008

Houston, Texas, United States

COMPLETEDPhase 3< 1 mile

Lethargic Depression Study

NCT00064467

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

EpilepsyMajor Depressive Disorder (MDD)

GlaxoSmithKline268 participantsStarted Jun 2003

Beverly Hills, California, United States • Sherman Oaks, California, United States • Temecula, California, United States +21 more locations

Depression Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221

The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.

Major Depressive Disorder

AstraZeneca542 participantsStarted Dec 2011

Chino, California, United States • Lond Beach, California, United States • San Diego, California, United States +41 more locations

COMPLETED< 1 mile

Ability to Cope With Type 1 Diabetes

NCT00206349

The purpose of this study is to learn about the relationship that exists between coping skills and blood glucose control. In addition to this, we will study the effect of Type 1 diabetes on coping skills in different age groups, genders, ethnicities, socioeconomic groups, and the duration of diabetes.

Baylor College of Medicine220 participantsStarted Jun 2004

Houston, Texas, United States

COMPLETEDPhase 3< 1 mile

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

NCT00868959

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression

Bipolar Depression

Sumitomo Pharma America, Inc.817 participantsStarted Apr 2009

Little Rock, Arkansas, United States • Anaheim, California, United States • Chino, California, United States +148 more locations

TERMINATEDPhase 2< 1 mile

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

NCT01128452

This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.

Janssen Research & Development, LLC8 participantsStarted Jun 2010

Oceanside, California, United States • San Diego, California, United States • Tampa, Florida, United States +11 more locations

COMPLETEDPhase 2< 1 mile

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095

The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).

Bristol-Myers Squibb976 participantsStarted Jul 2011

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Chino, California, United States +90 more locations

COMPLETEDPhase 46.5 miles

Sexual Functioning Study With Antidepressants

NCT00316160

Effects of two depression medication on sexual functioning

Depressive Disorder, MajorMajor Depressive Disorder (MDD)

GlaxoSmithKline347 participantsStarted Sep 2004

Mesa, Arizona, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +42 more locations

COMPLETEDPhase 319 miles

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01305408

The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.

Cephalon399 participantsStarted Mar 2011

Birmingham, Alabama, United States • Sherman Oaks, California, United States • Temecula, California, United States +127 more locations

COMPLETEDPhase 350 miles

Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

NCT01370733

This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5 days per week for 6 weeks. Subjects who complete 6 weeks of double-blind treatment may be eligible to receive up to four weeks of open label sTMS therapy or antidepressant medications during the follow-up phase of the study. Follow-up evaluation visits will be conducted during those four weeks, with the frequency of the visits determined by the treatment choice during that timeframe.

Major Depressive Disorder

Wave Neuroscience202 participantsStarted May 2012

Los Angeles, California, United States • San Diego, California, United States • Torrance, California, United States +15 more locations

COMPLETEDPhase 3146 miles

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708

This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).

Major Depressive Disorder

Pfizer283 participantsStarted Feb 2012

Birmingham, Alabama, United States • Tucson, Arizona, United States • Imperial, California, United States +33 more locations

COMPLETEDPhase 3146 miles

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01371734

This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

Major Depressive Disorder

Pfizer363 participantsStarted Aug 2011

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Tucson, Arizona, United States +39 more locations

COMPLETEDPhase 3146 miles

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

NCT02013531

The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.

Major Depressive DisorderAnxiety

Otsuka Pharmaceutical Development & Commercialization, Inc.37 participantsStarted Nov 2013

Tuscon, Arizona, United States • Garden Grove, California, United States • Oceanside, California, United States +18 more locations

COMPLETEDPhase 3189 miles

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346

The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment

Major Depression Disorder

H. Lundbeck A/S132 participantsStarted Mar 2015

Arcadia, California, United States • Miami, Florida, United States • Orlando, Florida, United States +31 more locations

COMPLETEDNA225 miles

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

NCT02452892

The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.

DepressionDepressive DisorderDepressive Disorder, Treatment-resistant+1 more

Tal Medical, Inc.122 participantsStarted Sep 2015

Garden Grove, California, United States • Lemon Grove, California, United States • Oakland, California, United States +9 more locations

COMPLETEDPhase 2225 miles

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850

This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue, anxiety and depression which worsen quality of life.

Anxiety DisorderDepressionFatigue+1 more

Alliance for Clinical Trials in Oncology21 participantsStarted Aug 2001

Anniston, Alabama, United States • San Diego, California, United States • Washington D.C., District of Columbia, United States +40 more locations

COMPLETEDPhase 3225 miles

Major Depressive Disorder With Mixed Features - Extension

NCT01423253

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.

Major Depressive Disorder

Sumitomo Pharma America, Inc.48 participantsStarted Sep 2011

Birmingham, Alabama, United States • Escondido, California, United States • Garden Grove, California, United States +14 more locations

COMPLETEDPhase 2225 miles

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

NCT01684163

GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.

Major Depressive Disorder

Naurex, Inc, an affiliate of Allergan plc369 participantsStarted Nov 2012

Birmingham, Alabama, United States • Encino, California, United States • Los Alamitos, California, United States +23 more locations

COMPLETEDNA442 miles

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NCT00022074

RATIONALE: Gabapentin may be effective for the control of hot flashes. It is not yet known if gabapentin is effective in treating hot flashes. PURPOSE: Randomized clinical trial to study the effectiveness of gabapentin in controlling hot flashes in women who have breast cancer.

Anxiety DisorderBreast CancerDepression+1 more

Gary MorrowStarted Jul 2001

Mobile, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +15 more locations

COMPLETEDPhase 3766 miles

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622

The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-placebo group (saredutant placebo in combination with escitalopram placebo).

Major Depressive Disorder

Sanofi643 participantsStarted Sep 2007

Bridgewater, New Jersey, United States • Buenos Aires, Argentina • Helsinki, Finland +3 more locations

PreviousPage 7 of 10Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia